Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth

Scholar Rock Holding Corporation SRRK President & CEO Jay Backstrom presented at the J.P. Morgan Healthcare Conference.The discussions mainly focused on apitegromab for spinal muscular atrophy (SMA), including its label if approved. They also covered commercial aspects such as the prevalence of SMA, the potential market, and factors influencing its adoption.Also Read: Scholar Rock’s Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next YearRegarding apitegromab in SMA, the company plans to ...